HRAS and ganglioneuroma: Importantly, these authors discovered that 20.0% (3/15) of the tumors studied by CP (PCC and ganglioneuroma) had BRAF mutations (K601E and K601N) and 46.7% (7/15) had HRAS mutations (Q61R, Q61L, G13R) based on genetic findings from the two cases studied by the NGS panel.